The Institute for Clinical and Economic Review (ICER) published a Draft Evidence Report regarding Biogen’s aducanumab. The drug is designed to treat Alzheimer’s disease and cost-effectiveness analyses indicate a modest improvement compared to other medications. However, the drug’s efficacy remains unclear. The Food and Drug Administration will likely issue its ruling next month.
ICER Chief Medical Officer Dr. David Rind remarks, “Nearly everyone has been touched by Alzheimer’s disease through its effects on family members, friends, colleagues, or themselves,” said adding, “It is a condition that people dread like no other, and the first therapy that effectively cures or stops the progression of the disease will warrant a very high price in the US health system. However, the clinical trial history and evidence regarding aducanumab are complex, and we believe that at the current time the evidence remains insufficient to determine whether the drug provides an overall health benefit. This is an area of tremendous unmet need, but this treatment has important side effects, and its wide use would have important ramifications for patients and health care budgets, making it all the more important that we know whether a therapy like aducanumab is, or is not, effective.” Read more here.
(Source: ICER, 5/5/21)